Emergent biosolution stock.

Mar 17, 2023 · Shares of Emergent BioSolutions ( EBS -4.11%) were sinking 12.8% lower as of 10:53 a.m. ET on Friday. The decline came after J.P. Morgan analyst Jessica Fye downgraded the stock from a neutral ...

Emergent biosolution stock. Things To Know About Emergent biosolution stock.

Mar 29, 2023 · Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%. Sep 7, 2023 · Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM), a stock from the same industry, has gained 16.4%. EBS earnings call for the period ending September 30, 2023. Image source: The Motley Fool. Emergent BioSolutions ( EBS 11.68%) Q3 2023 Earnings Call. Nov 08, 2023, 5:00 p.m. ET. Jul. 31, 2023, 05:14 PM. Emergent Biosolutions Inc (NYSE:EBS) shares are trading higher in Monday's after-hours session after the company was awarded a 10-year contract for development of an Ebola ...Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105. The stock fell to a low of $50 in late March when a rapid increase ...

EBS US29089Q1058 Pharmaceuticals Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds and ETFs -40% on all our …Emergent BioSolutions announced Thursday that the US Food and Drug Administration will allow it to resume the manufacturing of the drug substance that goes into Johnson & Johnson’s Covid-19 vaccine.

According to the issued ratings of 2 analysts in the last year, the consensus rating for Emergent BioSolutions stock is Reduce based on the current 1 sell rating and 1 hold rating for EBS. The average twelve-month price prediction for Emergent BioSolutions is $15.50 with a high price target of $22.00 and a low price target of $9.00.Mar 29, 2023 6:24 AM PDT. By Will Feuer. Shares of Emergent BioSolutions Inc. rose after the U.S. Food and Drug Administration said the company's overdose reversal medication Narcan could be sold ...

May 18, 2023 · Tasos Katopodis. Contract manufacturer Emergent BioSolutions ( NYSE: EBS) fell ~3% in early pre-market trading Thursday after announcing its plans to sell $150M shares of common stock under an ... Emergent Biosolutions Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Emergent Biosolutions Inc. Quarterly; Annual; Actual Analyst Range Consensus. 2.00 0.00-2.00. Actual-0.31 .2.14. Exchange. NYSE. 12/01/23 4:10 pm EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website contains information about Emergent …Nov 29, 2023 · 2 equities research analysts have issued 12-month price targets for Emergent BioSolutions' shares. Their EBS share price targets range from $9.00 to $22.00. On average, they anticipate the company's share price to reach $15.50 in the next year. This suggests a possible upside of 638.1% from the stock's current price. Contract drugmaker Emergent BioSolutions Inc said on Thursday it is aiming to price the over-the-counter (OTC) version of its opioid overdose reversal drug Narcan at around $50 per carton.

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the ...

Shares of Emergent Biosolutions ( EBS -0.47%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion-dollar agreement ...

Emergent BioSolutions Contacts: Media: Matt Hartwig Senior Director, Media Relations 240-760-0551 [email protected]. Investors: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected]. Source: Emergent BioSolutionsApr 10, 2023 · Benchmark upgraded Emergent BioSolutions Inc (NYSE:EBS) from Hold To Buy with a price target of $22 on the positive FDA and Narcan market news.; Related: FDA Approves First OTC Naloxone Nasal ... Legal Name Emergent BioSolutions Inc. Stock Symbol NYSE:EBS. Company Type For Profit. Contact Email [email protected]. Phone Number 240-631-3200. Emergent BioSolutions is a global life sciences company that is driven by a mission to protect and enhance life. It develops, manufactures, and delivers a portfolio of medical …Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses.EBS US29089Q1058 Pharmaceuticals Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds and ETFs -40% on all our …Government contracts account for 61% of the company's sales for much of 2020. Since 2016, government agencies have stockpiled up to $6.4 billion worth of Emergent BioSolutions' products, including ...Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Rapt Therapeutics RAPT, another stock in the same industry, closed the last trading session 2.7% higher at ...

Feb 25, 2022 · Emergent BioSolutions (EBS-6.98%) ended the week on a down note. Shares of the company closed 6.2% lower on Friday after it provided its fourth-quarter update following the market close on Thursday. Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 24.48% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $7.74. Over the last year, Emergent Biosolutions Inc has hit prices as high as $44.39 and as low as $7.74.Jul 20, 2023 · “The approval of CYFENDUS™ vaccine is symbolic of Emergent's longstanding partnership with the U.S. government and our shared commitment to helping protect public health,” said Dr. Kelly Warfield, Emergent’s senior vice president, science and development. “The 20-year journey from early development to approval is a major milestone ... Real time Emergent BioSolutions (EBS) stock price quote, stock graph, news & analysis.The stock price of government contractor Emergent BioSolutions has fallen sharply since the disclosure at the end of March that production problems at the firm’s plant in Baltimore had ruined 15 ...Jul 6, 2021 · 132. Last summer, investors flocked to the biotech company Emergent BioSolutions. The host of CNBC’s “Mad Money,” Jim Cramer, gushed about the Maryland business, which had secured a ...

EBS - Emergent Biosolutions Inc - Stock screener for investors and traders, financial visualizations.Crypto Sectors Contact Us U.S. markets closed +13.44 -23.27 Russell 2000 +11.00 Emergent BioSolutions Inc. (EBS) NYSE - Nasdaq Real Time Price. Currency in USD Follow 2W 10W 9M 2.1500 +0.1400...

Investors ran up stock in Gaithersburg, Maryland-based Emergent BioSolutions Wednesday, after the U.S. Food and Drug Administration approved opioid overdose treatment Narcan for over-the-counter ...Data delayed at least 15 minutes, as of Dec 01 2023 19:47 GMT. More ▽. Find More Stocks. Use ...Emergent Biosolutions Inc (EBS) stock is trading at $8.58 as of 11:21 AM on Monday, Mar 27, an increase of $0.48, or 5.93% from the previous closing price of $8.10. The stock has traded between $8.24 and $8.62 so far today. Volume today is light. So far 425,778 shares have traded compared to average volume of 1,546,652 shares.Find the latest Emergent BioSolutions Inc. (EBS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.If you're looking to buy high-flying coronavirus stocks at reasonable prices, Emergent BioSolutions is a fantastic choice. Zhiyuan Sun has no position in any of the stocks mentioned. The Motley ...Emergent Biosolutions belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ultragenyx RARE , closed the last trading session 3.7% higher at $39.07.Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%.Our Mission. At Emergent, we develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared, just in case they ever do.

Emergent Biosolutions Inc (EBS) stock is trading at $8.58 as of 11:21 AM on Monday, Mar 27, an increase of $0.48, or 5.93% from the previous closing price of $8.10. The stock has traded between $8.24 and $8.62 so far today. Volume today is light. So far 425,778 shares have traded compared to average volume of 1,546,652 shares.

Shares of Emergent BioSolutions (NYSE: EBS) were tumbling 10.6% lower as of 11:29 a.m. ET on Tuesday. The decline came after S&P Global's S&P Dow Jones Indices announced that Advance Auto Parts will replace Emergent BioSolutions in the S&P SmallCap 600 index. S&P Dow Jones Indices said that … See more

Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 6.4%.Shares of Emergent BioSolutions ( EBS -3.30%) were falling 4% as of 11:07 a.m. EDT on Thursday after sinking as much as 7.6% earlier in the day. The stock tumbled earlier this week after the ...Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021. Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and ...Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use. February 15, 2023 17:19 ET ...Emergent BioSolutions. Market Cap. $108M. Today's Change. (%) Current Price. $2.09. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from ...Feb 27, 2023 · Emergent Biosolutions (EBS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.32. This compares to earnings of $4.50 per share a year ago. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown.Get the latest Emergent Biosolutions Inc (ER4) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.11 thg 8, 2023 ... Why Emergent Biosolutions Inc's (EBS) Stock Is Down 4.20% ... One of the most dreaded feelings for an investor is when the stock they just bought ...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023. GAITHERSBURG, Md. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023 , at 5:00 pm eastern time to discuss the financial results for …The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in theApr 22, 2021 · The stock price of Emergent Biosolutions, a biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases, and opioid overdoses, has seen a 17% drop over the last ... Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Instagram:https://instagram. dexcom share pricebest venture capital courseslulu tickerbank of montreal bmo 17 thg 8, 2022 ... Emergent Biosolutions Inc's trailing 12-month revenue is $1.7 billion with a 17.5% profit margin. Year-over-year quarterly sales growth most ...NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. myrxj j snack foods Contract drugmaker Emergent BioSolutions Inc said on Thursday it is aiming to price the over-the-counter (OTC) version of its opioid overdose reversal drug Narcan at around $50 per carton. big wealth management firms Emergent BioSolutions Contacts: Media: Matt Hartwig Senior Director, Media Relations 240-760-0551 [email protected] Investors: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] aims to price over-the-counter Narcan at about $50. Get Emergent BioSolutions Inc (EBS.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading ...